Evidence map›Paper›PMID 40553304›Full record

ReviewCurrent gastroenterology reports2025

The Impact of Specialized Pro-Resolving Mediators on Disease Activity and the Risk of Associated Colorectal Carcinoma in Inflammatory Bowel Disease.

Jennifer Katz, Stephanie Gold, Vikram J Christian, Robert Martindale

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jennifer KatzNYU Langone Health, New York, NY, USA. Jennifer.katz@nyulangone.org.
Stephanie GoldIcahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Vikram J ChristianDepartment of Pediatrics, Division of Pediatric Gastroenterology, University of Minnesota, Minneapolis, MN, USA.
Robert MartindaleDepartment of Surgery, Oregon Health Sciences University, Portland, OR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe purpose of this review is to explore the role of specialized pro-resolving mediators (SPMs) in the resolution of inflammation in inflammatory bowel disease (IBD) focusing on their potential therapeutic benefits in these conditions. RECENT

findingsIBD is characterized by chronic inflammation and mucosal barrier dysfunction, driven by a dysregulated immune response. SPMs, which are derived from polyunsaturated fatty acids, have been identified as active agents in resolving inflammation without impairing immune function. Preclinical studies indicate that SPMs can reduce intestinal inflammation, but clinical data are still limited. Moreover, SPMs may influence colorectal cancer (CRC) by modulating tumor-promoting inflammation and enhancing chemotherapy response. SPMs offer a promising approach to inflammation resolution and mucosal healing in IBD and CRC. However, further research is necessary to better understand their therapeutic potential and to establish their clinical applicability in these diseases.

Indexed as

Colorectal NeoplasmsFatty Acids, UnsaturatedInflammation MediatorsInflammatory Bowel DiseasesHumansSpecialized Pro-Resolving MediatorsFatty Acids, UnsaturatedInflammation MediatorsInflammationInflammatory bowel diseaseSpecialized pro-resolving mediators

Identifiers

PMID40553304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.